Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,787,399
  • Shares Outstanding, K 834,938
  • Annual Sales, $ 3,811 M
  • Annual Income, $ 663,000 K
  • EBIT $ 825 M
  • EBITDA $ 1,025 M
  • 60-Month Beta 0.37
  • Price/Sales 2.87
  • Price/Cash Flow 12.68
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 45.33% (-27.14%)
  • Historical Volatility 16.53%
  • IV Percentile 30%
  • IV Rank 3.50%
  • IV High 815.48% on 11/28/25
  • IV Low 17.36% on 09/02/25
  • Expected Move (DTE 31) 1.06 (8.22%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 8
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 383
  • Open Int (30-Day) 414
  • Expected Range 11.86 to 13.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 1
  • High Estimate 0.16
  • Low Estimate 0.16
  • Prior Year 0.20
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.91 +1.32%
on 01/16/26
14.32 -8.66%
on 12/23/25
-1.10 (-7.76%)
since 12/19/25
3-Month
12.91 +1.32%
on 01/16/26
14.95 -12.49%
on 10/22/25
-1.67 (-11.32%)
since 10/20/25
52-Week
12.26 +6.69%
on 04/09/25
16.17 -19.11%
on 06/12/25
-1.82 (-12.21%)
since 01/17/25

Most Recent Stories

More News
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine...

RDY : 13.08 (+1.24%)
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts...

RDY : 13.08 (+1.24%)
Is Zoetis Stock Underperforming the Dow?

Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.

RDY : 13.08 (+1.24%)
ZTS : 124.31 (-0.27%)
$DOWI : 49,359.33 (-0.17%)
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025

Aurigene Oncology Limited , a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein...

RDY : 13.08 (+1.24%)
Dr. Reddy’s Laboratories to Announce Q2FY26 Results on October 24, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dr Reddy’s...

RDY : 13.08 (+1.24%)
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS

RDY : 13.08 (+1.24%)
COYA : 4.40 (+2.80%)
Dr. Reddy’s Q1FY26 Financial Results

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned...

RDY : 13.08 (+1.24%)
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...

SDZNY : 77.1350 (+1.95%)
RDY : 13.08 (+1.24%)
TEVA : 30.80 (-3.02%)
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...

SDZNY : 77.1350 (+1.95%)
RDY : 13.08 (+1.24%)
TEVA : 30.80 (-3.02%)
2 overlooked stocks that crushed earnings but traded lower

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

WHR : 85.50 (-1.87%)
BAC : 52.19 (-1.47%)
RDY : 13.08 (+1.24%)
NVS : 144.46 (+0.08%)
TEVA : 30.80 (-3.02%)
HSBC : 82.76 (+0.28%)
DB : 37.89 (-2.55%)
PFE : 25.46 (-0.74%)
BMY : 55.00 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through...

See More

Key Turning Points

3rd Resistance Point 13.17
2nd Resistance Point 13.12
1st Resistance Point 13.02
Last Price 13.08
1st Support Level 12.86
2nd Support Level 12.81
3rd Support Level 12.71

See More

52-Week High 16.17
Fibonacci 61.8% 14.68
Fibonacci 50% 14.22
Fibonacci 38.2% 13.75
Last Price 13.08
52-Week Low 12.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar